


# The potent anti-arthritic that's gentle on your patient



In the stomach LEDERFEN is present as fenbufen which is not a gastric irritant. In the liver, LEDERFEN is converted to long-acting metabolites which possess potent anti-inflammatory and analgesic activity.



- Exceptional gastro-intestinal tolerance
- No accumulation in patients with renal impairment
- Simple dosage
- Highly effective

# Lederfen<sup>\*</sup>

fenbufen

## The right choice for your older arthritic patients

### PRESENTATION

#### 300 mg Capsules

Dark blue capsules each containing 300 mg of fenbufen and printed "Lederle 300 mg" on both the cap and body.

#### USES

Lederfen is a potent non-steroidal anti-inflammatory and analgesic agent indicated for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.

#### DOSAGE AND ADMINISTRATION

##### Adults

Two capsules (600 mg) as a single daily dose or three capsules (900 mg) daily in divided doses. Many patients can be adequately controlled with a daily dosage of two capsules taken at night; whereas some may require an extra capsule in the morning.

It is unnecessary to modify the dosage of Lederfen in cases of mild to moderate renal impairment. Lederfen may therefore be used in elderly patients in whom renal impairment commonly occurs.

##### Children

Not recommended for administration to children under the age of 14.

#### CONTRA-INDICATIONS, WARNINGS ETC.

**Contra-indications:** Hypersensitivity to propionic acid anti-inflammatory drugs, or aspirin.

**Precautions:** As with other non-steroidal anti-inflammatory agents, Lederfen should be used with great caution in patients with a history or evidence of active peptic or intestinal ulceration, and only when considered essential in pregnant and nursing women.

**Warnings and adverse effects:** Lederfen is well tolerated by most patients and unlike other non-steroidal anti-inflammatory agents, is extremely unlikely to cause gastro-intestinal ulceration. However, adverse effects may include symptoms of gastro-intestinal intolerance such as nausea. Other reactions which have occurred infrequently include skin rash, dizziness, drowsiness and headache. Slight decreases in blood leucocytes, haemoglobin and

haematocrit, as well as slight increases in prothrombin time and eosinophils, have occasionally been recorded. Transient elevations in values of liver function tests have occurred in some patients.

**Drug interactions:** When single doses of aspirin 900 mg and Lederfen 500 mg are administered together, serum concentrations of Lederfen and its metabolites are reduced by 10-20%. Concomitant use of aspirin may require adjustment of dosage of Lederfen.

Lederfen is strongly protein bound. Although no clinically significant interactions have been noted as yet, practitioners should be alert to this possibility.

**Overdosage:** There is no experience with overdosage, consequently the signs, symptoms and treatment have not been identified. There is no specific antidote.

#### PHARMACEUTICAL PRECAUTIONS

Store at a temperature not exceeding 15°C in the original container. Keep lid tightly closed.

#### LEGAL CATEGORY

#### POM.

#### PACKAGE QUANTITIES

Bottle of 100. Basic NHS cost £16.24 per 100 capsules.

#### FURTHER INFORMATION

Lederfen is extremely unlikely to cause gastro-intestinal bleeding or ulceration since it is present in the stomach as fenbufen which is not a gastric irritant. Following absorption, fenbufen is converted into active metabolites whose prolonged duration of action (half-lives 10-17 hours) provide sustained anti-inflammatory and analgesic activity. Therefore in many patients, single oral doses given at night will provide adequate plasma levels to provide symptomatic relief of nocturnal pain and morning stiffness.

#### PRODUCT LICENCE NUMBER

0095/0043

#### PRODUCT AUTHORISATION NUMBER

37/26/2.

#### DATE OF PREPARATION OR

#### LAST REVIEW

November 1980.

<sup>\*</sup>Trademark

Further information is available on request to the company



Lederle Laboratories, a division of Cyanamid of Great Britain Limited  
Fareham Road, Gosport, Hants PO13 0AS Tel: (0329) 236131.



# How long must they wait for Froben?

Three years' use in General Practice has shown that Froben is very effective in the treatment of osteoarthritis – as it is in rheumatoid arthritis.

Froben, a potent inhibitor of prostaglandin biosynthesis, has the powerful analgesic and anti-inflammatory action needed to relieve the pain and stiffness of osteoarthritis.

Today, a substantial proportion of prescriptions for Froben are for elderly osteoarthritic patients.

The sort of patients you see almost every day.

Make Froben **your** first choice.

We strongly recommend it.

 The Boots Company Ltd., Nottingham

**Froben**  
flurbiprofen

## A power to use sooner than later

### Prescribing Information:

**Presentation:** Sugar-coated tablets, each containing either 50mg or 100mg of flurbiprofen. **Uses:** Froben is indicated in the treatment of rheumatoid disease, osteoarthritis and ankylosing spondylitis. **Dosage:** 150mg to 200mg daily in 3 or 4 divided doses. In patients with severe symptoms or disease of recent origin, or during acute exacerbations, the total daily dose may be increased to 300mg in divided doses. **Contra-indications, Warnings etc:** Froben should not be given to patients with peptic ulceration. Care should be taken when administering the drug to patients with asthma or who have experienced bronchospasm with other anti-inflammatory or analgesic agents. The safety of Froben during pregnancy or lactation has not been established. In animal experiments, no teratogenic effects were demonstrated but parturition was delayed and prolonged. Side-effects: dyspepsia, heartburn and headache are the commonest encountered. Occasional skin rashes have been reported. Treatment of overdosage: gastric lavage and, if necessary, correction of serum electrolytes. There is no specific antidote. **Basic NHS Price:** 50mg tablets, 100 £8.24 100mg tablets, 100 £15.65. **Product Licence No:** 50mg tablets, PL0014/0167, 100mg tablets, PL0014/0168. Further information is available on request.



# Rheumatology

INTERNATIONAL

Clinical and Experimental Investigations

ISSN 0172-8172

Title No. 296

## Edited by

E. G. L. Bywaters, London; K. Fehr, Zurich; J. R. Kalden, Erlangen;  
E.-M. Lemmel, Mainz; K. D. Muirden, Melbourne; J. B. Natvig, Oslo; C. Steffen,  
Vienna; R. Winchester, New York; M. Ziff, Dallas  
In cooperation with a distinguished editorial board

Recent years have witnessed a steady increase of insight into the mechanisms underlying the various rheumatic diseases. This development is due to progress achieved in different fields of basic research as well as to improved means and methods for clinical evaluation, diagnosis, observation, and treatment of the individual case.

RHEUMATOLOGY INTERNATIONAL, an independent journal reflecting progress in these fields world-wide, is designed to serve the international and interdisciplinary group of workers engaged with problems of rheumatic diseases.

RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical and experimental research as well as in the management of the rheumatic diseases. Special emphasis will be given to immuno-pathogenetic mechanisms, inflammatory reactions, collagen metabolism, genetics, epidemiology, therapeutic modulation of immunological and inflammatory mechanisms, and development and evaluation of diagnostic procedures connected with the rheumatic diseases. Contributions to these topics will appear in the form of original publications, informative case reports, short communications, editorials, and reviews. "Letters to the editor" will be welcome as enhancement to discussions. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.

## Subscription Information

1981, Volume 1 (4 issues): DM 120.00, plus postage and handling.

Please send your order to your bookseller or directly to:

Springer-Verlag, P.O. Box 105 280, D-6900 Heidelberg, FRG

## North America

US \$ 76.00, including postage and handling.

Orders from North America should be addressed to:

Springer-Verlag New York Inc., Journal Sales Department, 44 Hartz Way,  
Secaucus, NJ 07094, USA



Springer  
International

## Coupon

return to: Springer-Verlag, P.O. Box 105 280, D-6900 Heidelberg 1, FRG  
or to your bookseller

## Rheumatology International

- ☐ Please enter my subscription for Volume 1 (4 issues)  
DM 120.00, plus postage and handling
- ☐ Please send a sample copy
- ☐ Please send Guidelines for Authors

(Give complete address)



1624/S/1A



# **VOLTAROL 50**

diclofenac sodium

## **The symbol of a new flexibility**

**Eases rheumatic pain and stiffness**

**Improves mobility**

**Flexible dosage**

### **Geigy**

Full prescribing information is available from  
Geigy Pharmaceuticals, 54 Northumberland Road, Ballsbridge, Dublin.

# METHRAZONE<sup>®</sup> HAS THE STRENGTH

feprazone

There's a strong case for including Methrazone in your armamentarium of anti-arthritic agents. Methrazone reinforces your choice of treatment, providing effective relief from the chronic problem of pain, stiffness, inflammation and immobility.

Unlike many other anti-arthritic agents introduced in recent times, Methrazone is founded on strength. Chemically its starting point lies in phenylbutazone. But Methrazone is a whole generation different from phenylbutazone – chemically and clinically. Its one strong similarity to phenylbutazone is a high degree of anti-inflammatory activity.

As befits a modern anti-arthritic, Methrazone has a low incidence of major adverse effects – and has stood up strongly to a particularly searching scrutiny of its safety in short- and long-term monitored programmes. Adding Methrazone to the armamentarium can only strengthen your choice.

**PRESCRIBING INFORMATION:** Methrazone – feprazone capsules 200mg. **Action and Indications:** Non-steroidal anti-inflammatory agent for rheumatoid arthritis and osteoarthritis. **Contra-indications:** Where there is a danger of cardiac decompensation; hepatic disease; history of peptic ulceration; blood dyscrasia; drug rash or known sensitivity to pyrazoles. **Precautions, Warnings and Side effects:** Concurrent therapy with plasma protein-bound agents; as for all pyrazole drugs, blood monitoring and surveillance for sodium and water retention are advised; caution in pregnancy during organogenesis. Mild gastric intolerance, rashes, and occasional headache have been reported. **Dosage:** Adults only: 200-600mg daily in divided doses by mouth after food. **Pack size and basic NHS price (UK only)** 100 capsules, £12.87. PL 0015/0071 ▼  
For full prescribing information please see data sheet. **WB Pharmaceuticals Ltd**  
PO Box 23 Bracknell Berkshire RG12 4YS.



**REALLY ACTIVE  
IN ARTHRITIS**



# Brufen 400

Ibuprofen B.P.

The Great British  
Workhorse in arthritis

## PUZZLED PRESCRIBER:

*Horses? A Ploughman?  
Are you indicating that  
these rural operatives are  
more than usually prone  
to rheumatic ailments?*

## AGRONOMICALLY INCLINED ADVERTISER:

*'It occurred to us that, as a Physician,  
you would not be greatly attracted by  
photographic depictions of simulated  
surgery scenes and the like. Our amiable  
rustic and his equine colleagues are  
intended to convey analogically that,  
when it comes to the treatment of  
painful rheumatic conditions (be it in  
urban or rural practice), Brufen is a most  
efficient and reliable drug.'*

1 tablet  
3-4 times  
daily

**Prescribing Information.** **Presentation** Brufen 400 are sugar-coated tablets each containing 400mg of Ibuprofen B.P. The tablets are light magenta in colour and bear the overprint 'Brufen 400' in black. **Uses** Brufen is indicated for its anti-inflammatory and analgesic effect in the treatment of rheumatoid arthritis (including Juvenile rheumatoid arthritis or Still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthropathies. In the treatment of non-articular rheumatic conditions, Brufen is indicated in periarthritic conditions such as frozen shoulder (capsulitis), bursitis, tendinitis, tenosynovitis and low back pain; it can also be used in soft tissue injuries such as sprains and strains. **Dosage and Administration** Adult: The recommended initial dosage of Brufen is 1200 mg daily in divided doses. Some patients can be maintained on 600 to 1200 mg daily. It can be advantageous in severe conditions to increase the dosage to 1600 mg daily in divided doses until the acute phase is brought under control. Children: 20 mg of Brufen per kg of body weight daily, except that in children weighing less than 30 kg, the total dose of Brufen given in 24 hours should not exceed 500 mg. **Contra-indications** Brufen should not be given to patients with severe or active peptic ulceration. **Use in Pregnancy** No teratogenic effects have been demonstrated in animal experiments; nevertheless, the use of Brufen during pregnancy should be avoided if possible. **Warnings and Adverse Effects** Brufen should be prescribed with caution for patients with asthma and especially for those who have developed bronchospasm with other non-steroidal agents. The adverse effects reported include dyspepsia, gastro-intestinal intolerance and bleeding and skin rashes of various types. Less frequently, thrombocytopenia has occurred. A very rare occurrence can be toxic amblyopia, but in reported cases, recovery occurred upon cessation of treatment. **Treatment of Overdosage** Gastric lavage, if necessary, correction of blood electrolytes. There is no specific antidote to Brufen. **Pharmaceutical Precautions** Recommended storage conditions: 5 °C to 20 °C. **Legal Category** POM. **Package Quantities** 400 mg tablets (Brufen 400): tin of 100, tin of 250. **Further Information** When Brufen is taken on an empty stomach, the peak serum levels occur 45 minutes after ingestion whereas when taken after a meal the peak is delayed to 90 minutes. Consequently, as most patients can take Brufen on an empty stomach without gastric discomfort, if the first daily dose is taken on awakening with a drink, the rapid absorption of the drug will help to relieve morning stiffness. **Basic NHS Price** Brufen 400, 250 Pack £11.54. **Product Licence Numbers** 400 mg tablets (Brufen 400): PL0014/0158.

# FLENAC

**a step beyond  
symptomatic relief**

These studies show Flenac to have a beneficial effect on E.S.R. and on C-reactive protein and Rheumatoid Factor titres – the laboratory parameters considered to best reflect disease activity and correlate with radiological evidence of joint damage<sup>5</sup>

# reducing eventual joint damage

**relieving pain  
and  
inflammation**



# TRILISATE®

CHOLINE MAGNESIUM TRISALICYLATE TABLETS

## FOR ARTHRITIS



From now on,  
aspirin is only for headaches.

#### **PRESCRIBING INFORMATION:**

**PRESENTATION:** Pale orange capsule-shaped, scored tablets with TRILISATE on one side and NAPP 500 on the other, containing 500mg salicylate as choline magnesium trisalicylate.

**USES:** TRILISATE tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and other arthroses.

**DOSAGE AND ADMINISTRATION:** Two tablets twice a day for osteoarthritis and mild to moderate arthroses. Three tablets twice a day for rheumatoid arthritis and the more severe arthroses.

**CONTRA-INDICATIONS, WARNINGS, ETC:**

**CONTRA-INDICATIONS:** Hypersensitivity

to aspirin. Active peptic ulceration. Haemophilia.

**PRECAUTIONS:** Concurrent administration with other analgesics containing aspirin. As with other salicylates, TRILISATE tablets should be used with caution in patients with chronic renal insufficiency, or with erosive gastritis or peptic ulcer.

TRILISATE tablets should be used with caution in pregnancy.

#### **WARNINGS AND ADVERSE EFFECTS:**

May induce gastro-intestinal haemorrhage. Reports indicate that when salicylates are given with steroids, the butazones or alcohol, the risk of gastro-intestinal ulceration is increased.

TRILISATE tablets are not recommended for

children under twelve years of age. As with all medicines, TRILISATE tablets should be kept out of reach of children.

#### **TREATMENT OF OVERDOSAGE:**

Empty stomach contents and lavage stomach with 5% sodium bicarbonate solution.

Severe overdosage should be treated by diuresis induced by intravenous saline with sodium bicarbonate, or dextrose solution.

Electrolyte levels and acid base balance should be monitored and corrected as necessary.

#### **PHARMACEUTICAL PRECAUTIONS:**

TRILISATE tablets should be stored in a cool, dry place, protected from light.

**LEGAL CATEGORY:** P

**PACKAGE QUANTITIES:** Containers of 60 tablets.

#### **FURTHER INFORMATION:**

When TRILISATE tablets are administered, the salicylate is absorbed rapidly and reaches peak blood levels within two hours. At recommended doses, the therapeutic range of 5 to 30mg/100ml is achieved, and a steady state condition is normally reached after 4-5 doses.

TRILISATE tablets do not cause any significant faecal blood loss nor do they affect platelet aggregation.

TRILISATE tablets do not cause any observable stomach mucosal irritation as determined by endoscopic examination.

Basic NHS cost: 27.5p/day (2 b.d.)

**NAPP**

Further information is available on request from Napp Laboratories Limited, Hill Farm Avenue, Watford WD2 7RA, England.

Member of Napp Pharmaceutical Group. ® Trilisate is a registered trade mark. © Napp Laboratories Limited 1980. PL 0337/0053.

**Presentation** MERALEN 100mg  
Hard gelatin capsule with light  
blue body and dark blue cap  
**Composition** Each 100mg  
capsule contains: Flufenamic Acid  
BP 100mg

**Action** MERALEN is an anti-  
inflammatory analgesic known  
chemically as N-(4- $\alpha$ -trifluoro-  
m-tolyl)anthranic acid.

**Indications** For the relief of pain  
in rheumatoid arthritis,  
osteoarthritis and ankylosing  
spondylitis.

**Dosage and administration**  
(Oral) Adults: 600mg daily in  
divided doses, preferably with  
food. After four weeks continuous  
therapy reduced maintenance  
dosage of 400mg daily may be  
satisfactory in some patients. For  
those weighing less than 45kg  
(100lb) a dosage should not  
exceed 10mg per kg body weight  
daily. *Children* MERALEN should  
not be given to children of 14  
years or less.

**Contra-indications, warnings,  
etc.** Contra-indicated in  
pregnancy, in inflammatory bowel  
disease and in patients suffering  
from gastric and/or intestinal  
ulceration and in renal or hepatic  
disease.

**Precautions** Concurrent therapy  
with other plasma protein binding  
drugs, eg. anti-coagulants, may  
necessitate a modification in  
dosage.


**Warnings and Adverse Effects**  
Discontinue administration of  
MERALEN if diarrhoea or  
abnormalities in liver function tests  
occur. The commonest side effect  
is gastro-intestinal upset  
characterised by nausea, vomiting  
or epigastric discomfort. If gastro-  
intestinal intolerance occurs and  
the physician attributes this to the  
drug, the dose of MERALEN may  
be reduced by one half. If signs  
and symptoms do not subside, the  
drug may need to be completely  
discontinued. The physician may  
be able to increase the daily  
dosage of MERALEN again once  
these symptoms have subsided.  
In some patients the gastro-  
intestinal symptoms subside  
spontaneously without a change of  
the dose of MERALEN.

MERALEN should be discontinued  
in the event of rash suspected to be  
a sensitivity reaction. One case  
of purpura and four of leucopenia  
have been reported; one of the  
latter had been diagnosed as  
spontaneous leucopenia before  
MERALEN therapy had  
commenced. Bronchospasm may  
be precipitated in patients  
suffering from or with a previous  
history of bronchial asthma or  
allergic disease.

**Treatment of overdosage**  
Gastric lavage in the conscious  
patient and intensive supportive  
therapy where necessary.  
Activated charcoal has been  
shown to be a powerful adsorbent  
for MERALEN and its metabolites.  
Studies in experimental animals  
showed that a 5 to 1 ratio of  
charcoal resulted in considerable  
suppression of absorption of the  
drug.

**Pharmaceutical precautions**

No special storage precautions.

**Legal category** 

**Package Quantities** 100mg  
capsules available in a pack of  
100 capsules.

**Basic NHS cost** £4.40 for 100  
capsules (June 1979).

**Product Licence No.** MERALEN  
Capsules 100mg: 0027/0034

**References:** 1. Focus on  
Rheumatology (1978),  
Supplement to Doctor; 2. Van  
Collier P.E. (1970) *Medical  
Proceedings*, 16, 342.

Merrell Division, Richardson  
Merrell Ltd, 20 Queensway,  
Slough, Berks, SL1 1YU.

Merrell and Meraleen are trade  
marks.

## Anti-inflammatory Analgesic Capsules Flufenamic Acid BP

# the valid alternative in arthritis

You and your arthritic patient will have  
experienced the time-consuming search  
through the available non-steroidal  
armamentarium for the drug "...which  
combines optimal effectiveness and absence  
of adverse effects."<sup>1</sup>

**MERALEN** may just be the right drug for many  
of your arthritic patients.

**MERALEN** belongs to the fenamates, totally  
unrelated to the propionic acid derivatives,  
salicylates and phenyl-pyrazolone derivatives.

"Flufenamic acid (**MERALEN**) appears to be  
useful as an anti-rheumatic drug, especially in  
rheumatoid and osteo-arthritis, where  
long-standing pain and joint inflammatory  
processes were still active. It gives relief and  
even enhances mobility where joint pathology  
incapacitates movement."<sup>2</sup>

## Drugs and Disease

The Proceedings of a Symposium  
organised by the  
Royal College of Pathologists

Edited by  
Sheila Worlledge

Price: Inland £3.00  
Abroad US \$7.50  
*including postage*

The Publishing Manager, JOURNAL OF  
CLINICAL PATHOLOGY, BMA House,  
Tavistock Square, London WC1H 9JR

## SPAS IN ITALY ABANO- MONTEGROTTO

FOR HEALTH AND HOLIDAYS

The attractively situated Veneto Spas (25 miles from Venice) are renowned for their mud pack (fango) and thermal treatment for rheumatism and arthritis. 110 hotels in all price categories. Every hotel has one or more thermal pools and treatment facilities under medical supervision. Varied excursion programme (Venice, Palladian Villas, Dolomites, Florence and Verona—with tickets for opera). Golf course (18 holes) at the foot of the Euganean Hills.

*For full information contact the Spa representative—*

**Miss Erna Low**

9 (RD) Reece Mews,  
London SW7 3HE

Tel: 01-584 2841 (24 hours)

Bookings through ABTA Agents

## Diseases of Connective Tissue

*The Proceedings of a Symposium organised by  
The Royal College of Pathologists*

**Edited by D. L. Gardner**

**The cells**—Fibroblasts ● Chondrocytes ● Synoviocytes ● The muscle cell ● **Extracellular materials**—Collagens ● Collagen and elastin fibres ● Basement membrane ● Proteoglycans of cartilage ● **Disease mechanisms**—Diseases of the collagen molecule ● Molecular abnormalities of collagen ● Lysosomes and the connective-tissue diseases ● **Genetic disease**—HLA system and rheumatic disease ● Replacement therapy in the mucopolysaccharidoses ● Genetic disease and amyloid ● **Inflammation and fibrosis**—Rheumatoid arthritis—a virus disease? ● Systemic lupus erythematosus—an autoimmune disease? ● Hepatic cirrhosis—a collagen formative disease? ● Fibrosis of lung—an environmental disease? ● **Kettle Memorial Lecture**—Atherosclerosis—disease of old age or infancy? ● **Structural and metabolic disease**—New knowledge of connective tissue ageing ● New knowledge of osteoarthritis ● New knowledge of intervertebral disc disease ● New knowledge of the pathogenesis of gout ● New knowledge of chondrocalcinosis ● **A consensus**—Connective tissue diseases: A consensus.

**Price: Inland £6.00; Abroad US\$15.00, including postage**

Payment must be enclosed with order or a surcharge of 50p will be made for rendering invoices and statements

The Publisher, *Journal of Clinical Pathology*, B.M.A. House, Tavistock Square,  
London WC1H 9JR